nDatalyze Corp. Announces appointment of a new President and Director, the resignation of a current Director, and Stock Option Grants
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
nDatalyze (NDATF) named D’Arcy Funfer as president and CEO and appointed him to its board, with both appointments effective immediately. Funfer succeeds Gordon Crawford as a director, while outgoing president and CEO Jim Durward remains board chair.
The company has spent the past six months developing EpitomePD, its athletic assessment platform, and said it can now focus on commercialization, starting with hockey. The platform is designed to help amateur hockey players make more informed training decisions and can be used in other sports and high-performance markets.
nDatalyze granted 3,700,000 stock options to directors and officers under its stock option plan. The options have an exercise price of $0.05 per common share, expire two years from the grant date and are subject to a four-month hold period from that date.
Positive
- Minor point. Forward-looking: it has not happened yet and may not happen.EpitomePD commercialization is the company’s next focus after six months of development, starting with hockey.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.3,700,000 stock options granted to directors and officers could dilute existing shareholders if exercised at $0.05 per common share.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Calgary, Alberta – TheNewswire - November 18, 2026. nDatalyze Corp. (CSE: NDAT. OTC: NDATF) (“NDAT” or the “Corporation”) announces that, effective immediately, D’Arcy Funfer will become the Corporation’s President and CEO. Jim Durward, the outgoing President and CEO, will stay on as Chairman of the Board of Directors. Mr. Funfer will also succeed Gordon Crawford as a Director and the Corporation thanks Mr. Crawford for his service and wishes him well in his endeavors.
Over the past six months, the corporation has been quietly developing its advanced athletic assessment platform (“EpitomePD”) and can now focus on the commercialization phase. EpitomePD can address multiple sports and other high human performance markets, with the initial focus being Hockey. The EpitomePD website is at https://www.epitomepd.com/
Mr. Funfer, the new President, states: “I’m grateful to nDatalyze’s Board of Directors for entrusting me with the role of President and CEO. What excites me about EpitomePD is its goal of helping individual amateur hockey players better understand how they are built so they can develop smarter. By bringing together insights into a player’s mindset, genetic predispositions, and environmental development, the platform helps players, families, and coaches make more informed training decisions. I’m honoured to lead EpitomePD as we bring this approach to more players and hockey organizations across North America and beyond.”
The Corporation has granted an aggregate of 3,700,000 stock options to its directors and officers, pursuant to the Corporation’s stock option plan, at an exercise price of
and expiring two years from the date of grant. The stock options are subject to a customary four month hold period from the date of grant.
About nDatalyze Corp.
nDatalyze Corp. is a technology company focused on developing health and performance-related solutions through the application of artificial intelligence and biometric data analytics, including the Epitome sports performance platform (https://www.epitomepd.com)
For Further Information, please contact:
D’Arcy Funfer, President and CEO
Email: dsfunfer@gmail.com
Tel: (403) 828-2200
For technical matters: Jim Durward, Chairman of the Board of Directors
Email: jimd@ndatalyze.com
Tel: (403) 689-3901
nDatalyze Website: https://www.ndatalyze.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
The information in this news release includes certain information and statements about management’s view of future events, expectations, plans and prospects that constitute forward-looking statements, including statements regarding the return of escrowed subscription proceeds, the reinstatement of trading of the Company’s common shares on the Canadian Securities Exchange and the commercialization of the Epitome platform. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward-looking statements. Although the Corporation believes that the expectations reflected in forward-looking statements are reasonable, it can give no assurances that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Corporation disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.
Copyright (c) 2026 TheNewswire - All rights reserved.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.